SCHEMBL23489604

SCHEMBL23489604

O[C@H](CF)c1cccc(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ADRB3 P13945 6/20 0.47
ADRB1 P08588 5/20 0.47
ADRB2 P07550 3/20 0.47
SLC2A1 P11166 2/20 0.46
IDO1 P14902 2/20 0.44
LMNA P02545 1/20 0.44
ACP3 P15309 1/20 0.43
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1154749 0.83 ADRB3 (0.49) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL767795 0.83 ADRB3 (0.49) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL2879198 0.83 ADRB3 (0.49) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL8098427 0.82 ADRB3 (0.48) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL7105071 0.82 ADRB3 (0.48) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL7107297 0.82 ADRB3 (0.48) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL3917396 0.82 ADRB3 (0.48) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL98267 0.82 ADRB3 (0.48) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL1560927 0.82 ADRB3 (0.48) ADRB3ADRB1ADRB2SLC2A1IDO1
SCHEMBL3489554 0.80 PNMT (0.56) ADRB3ADRB1ADRB2SLC2A1IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2023-07-06 US disclosed
US-11548871-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof GILEAD SCIENCES, INC. (US) 2023-01-10 US disclosed
US-20210171500-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF GILEAD SCIENCES, INC. 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11548871-B2 Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof LPAR3, LPAR1, LPAR2 ADRB3 1098/4885ADRB1 1694/4885ADRB2 2406/4885
US-20210171500-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR3, LPAR1, LPAR2 ADRB3 1098/4885ADRB1 1694/4885ADRB2 2406/4885
US-20230212149-A1 TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF LPAR3, LPAR1, LPAR2 ADRB3 1098/4885ADRB1 1694/4885ADRB2 2406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.